The Relational Sequencing TB Consortia launched the ReSeqTB Data Platform to data contributors and the Rapid DST Consortia. This novel Platform catalogs extensive genotypic, phenotypic and related metadata from Mycobacterium tuberculosis (M.tb) strains. Open access to standardized and validated data will streamline the development of clinically useful, WHO-endorsed in vitro diagnostic assays for rapid drug susceptibility M.tb tests. ReSeqTB has implemented a whole genome sequencing (WGS) analysis pipeline with associated metadata for global M.tb strains to functions as a “one stop” source for curated, aggregated and clinically relevant genetic data.
Achieving this milestone is important because this platform will lead to optimized studies that will accelerate the development of rapid drug susceptibility tests for TB. The ReSeqTB Data Platform is also noteworthy because it will enable significantly quicker diagnosis of drug resistant disease in TB patients and lead to more effective treatment regimens. Within the next year ReSeqTB will improve the platform by including additional analytic tools and aggregated reports. The ReSeqTB Data Platform is on track to launch globally in the second half of 2016.